Pharmas worrying whether to unveil successful outcomes in this political situation
“Should we, or shouldn’t we…”
Pharmaceutical companies have a concern lately. It is whether they should announce successful outcomes, which were created by R&D with great ef forts and challenges to the global market, in the market right now or postpone it for a while.
It is true these concerns ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
